Novel Biomarkers in Rheumatoid Arthritis
类风湿关节炎的新型生物标志物
基本信息
- 批准号:8468995
- 负责人:
- 金额:$ 16.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-11 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAllelesAntibodiesAntibody FormationAntigen-Antibody ComplexAntigensArginineAutoantibodiesB-Cell ActivationB-LymphocytesBiological MarkersBloodCXCL13 geneCellular biologyCitrullineClinicalComplementComplexCopy Number PolymorphismDevelopmentDiploidyDiseaseEpitopesFailureFrequenciesFunctional disorderGene DosageGenesGeneticGenomeHLA-DRB1HumanHyperactive behaviorHypergammaglobulinemiaImmunoglobulin GLeadLinkLinkage DisequilibriumMediatingMediator of activation proteinModelingNatureOnset of illnessOutcomePathogenesisPatientsPhenotypePhysiologicalPlayPopulationProteinsPublic HealthRelative (related person)Rheumatoid ArthritisRisk FactorsRoleSerumSeveritiesSeverity of illnessShapesStructure of germinal center of lymph nodeSystemic Lupus ErythematosusTestingUnited StatesVariantamino groupautoreactive B cellbasecarbonyl groupchemokinecohortdisease phenotypehuman subjecthydroxyl groupinnovationnovelresponsethioestertrafficking
项目摘要
DESCRIPTION (provided by applicant): This proposal tests a novel and innovative hypothesis in Rheumatoid Arthritis (RA) pathobiology. Specifically, we examine the role of complement C4B gene copy number variation (CNV) on RA pathogenesis and its interaction with HLA-DRB1 alleles (e.g. the shared epitope) in influencing RA phenotype (disease severity, B cell hyperactivity). Complement C4 proteins (C4A, C4B) are functionally distinguished by the nature of the covalent linkage they form with their targets: amino (C4A) vs thioester (C4B). Among their many essential roles, the acidic C4A and the basic C4B are important for the clearance of immune complexes. A deficiency of C4A is a well-established risk factor for human SLE, but the physiologic impact of C4B deficiency is under-studied. A diploid genome of a human subject contains zero to four copies of the C4B gene; serum levels of C4B strongly correlate with the number of C4B genes. In a RA population at Dartmouth, we observed that C4B deficiency (0-1 copy) is present in 43% of the seropositive patients, 31% of seronegative RA patients and 20% of non-RA patients or healthy controls (OR from 2.5 to 2.8). We hypothesize a particular role for C4B relative to C4A in RA mediated by its ability to clear immune complexes made up of anti-citrullinated protein antibodies (ACPA) and citrullinated antigens. We propose that the presence of deiminated-Arginines (i.e. citrullines with decreased numbers of amino groups) in these complexes results in a reduced ability of C4A to contribute to their clearance. As a result, the ability of the C4B-thioester carbonyl group to form a covalent linkage with a hydroxyl group of substrates for disposal makes C4B of much greater importance than C4A in the clearance of ACPA-immune complexes. Thus, deficient ACPA-based immune complex clearance associated with C4B deficiency would particularly enhance and favor maturation of anti-ACPA responses, promoting both seropositive RA and B cell hyperactivity. Hypothesis: We propose that C4B deficiency influences RA disease pathogenesis independent of the shared epitope (Aim 1). In Aim 2, we propose that C4B deficiency shapes RA phenotype and B cell hyperactivity (serum CXCL13, IgG and autoantibody levels).
描述(由申请人提供):该提案检验了类风湿关节炎(RA)病理生物学中的新颖而创新的假设。具体而言,我们研究了补体C4B基因拷贝数变化(CNV)对RA发病机理的作用及其与HLA-DRB1等位基因(例如共享表位)在影响RA表型(疾病严重程度,B细胞多动物)中的相互作用。补体C4蛋白(C4A,C4B)在功能上以它们与目标形成的共价连锁的性质区分:氨基(C4A)与硫酯(C4B)。在其许多基本作用中,酸性C4a和基本C4B对于清除免疫复合物很重要。 C4A的缺乏是人类SLE的一个公认的危险因素,但是C4B缺乏的生理影响不足。人类受试者的二倍体基因组包含C4B基因的四个副本。 C4B的血清水平与C4B基因的数量密切相关。在达特茅斯(Dartmouth)的RA人群中,我们观察到43%的血清阳性患者中存在C4B缺乏症(0-1拷贝),31%的血清染色RA患者和20%的非RA患者或健康对照组(或2.5至2.8)。我们假设C4B相对于C4A在RA中的特定作用,这是由于其清除由抗硝化蛋白抗体(ACPA)和瓜氨酸抗原组成的免疫复合物的能力。我们建议在这些复合物中存在能力性的 - 精氨酸(即氨基数量减少)的存在导致C4a有助于其清除率的能力降低。结果,在清除ACPA-rimmune复合物中,C4B- thioeser羰基与羟基底物形成共价连接的能力比C4A更重要。因此,与C4B缺乏症相关的基于ACPA的免疫复杂清除率不足将特别增强和有利于抗ACPA反应的成熟,从而促进血清阳性RA和B细胞多动。假设:我们建议C4B缺乏影响RA疾病发病机理,而与共享表位无关(AIM 1)。在AIM 2中,我们提出C4B缺乏型会塑造RA表型和B细胞多动(血清CXCL13,IgG和自身抗体水平)。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.
- DOI:10.1186/ar4552
- 发表时间:2014-04-25
- 期刊:
- 影响因子:4.9
- 作者:Jones JD;Hamilton BJ;Challener GJ;de Brum-Fernandes AJ;Cossette P;Liang P;Masetto A;Ménard HA;Carrier N;Boyle DL;Rosengren S;Boire G;Rigby WF
- 通讯作者:Rigby WF
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM FREDERICK CARSON RIGBY其他文献
WILLIAM FREDERICK CARSON RIGBY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM FREDERICK CARSON RIGBY', 18)}}的其他基金
Novel Targets of the Von Hippel Lindau Gene
Von Hippel Lindau 基因的新靶标
- 批准号:
6623380 - 财政年份:2002
- 资助金额:
$ 16.75万 - 项目类别:
Novel Targets of the Von Hippel Lindau Gene
Von Hippel Lindau 基因的新靶标
- 批准号:
7046099 - 财政年份:2002
- 资助金额:
$ 16.75万 - 项目类别:
相似国自然基金
等位基因聚合网络模型的构建及其在叶片茸毛发育中的应用
- 批准号:32370714
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于等位基因非平衡表达的鹅掌楸属生长量杂种优势机理研究
- 批准号:32371910
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACR11A不同等位基因调控番茄低温胁迫的机理解析
- 批准号:32302535
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠杆菌多粘菌素异质性耐药中phoPQ等位基因差异介导不同亚群共存的机制研究
- 批准号:82302575
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 16.75万 - 项目类别:
The immunogenicity and pathogenicity of HLA-DQ in solid organ transplantation
HLA-DQ在实体器官移植中的免疫原性和致病性
- 批准号:
10658665 - 财政年份:2023
- 资助金额:
$ 16.75万 - 项目类别:
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 16.75万 - 项目类别:
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
- 批准号:
10568344 - 财政年份:2023
- 资助金额:
$ 16.75万 - 项目类别:
Intravitreal gene therapy for inherited retinal disease
遗传性视网膜疾病的玻璃体内基因治疗
- 批准号:
10660784 - 财政年份:2023
- 资助金额:
$ 16.75万 - 项目类别: